Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Inclusion Criteria: 1. Patient has documented diagnosis of advanced solid tumor for which no standard systemic therapy exists 2. Patient has normal or abnormal hepatic organ function 3. Patient has provided written informed consent prior to any screening procedures Exclusion Criteria: 1. Patient needing valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat dose 2. Patient received prior treatment with DAC inhibitors including panobinostat 3. Patient requires treatment with warfarin that cannot be switched to another anticoagulant treatment prior to starting study drug 4. Patient has encephalopathy 5. Patient has ascites requiring intervention 6. Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment. Other protocol-defined inclusion/exclusion criteria may apply.